Psoriasis can be painful and interfere with sleep, and people with it may lose confidence in their physical appearance. The ...

unlocking a sizeable new market for the drug, which has been approved since 2014 for moderate to severe cases. Use in the milder end of the psoriasis spectrum gives Otezla a swathe of patients who ...

and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $2.3 billion oral psoriasis therapy Otezla (apremilast). BMS has previously said it ...

An experimental pill developed by Johnson & Johnson ... “superior” to oral drugs like Sotyktu and Otezla that are approved for psoriasis. However, the analyst wrote in a client note Tuesday ...

Much will depend on how many indications the company can line up for the oral immunosuppressant beyond its 2022 FDA approval to treat moderate-to-severe plaque psoriasis. To that end, the company ...

Giz Hol Nigt Hol An Win Otezla, an oral therapy for mild to moderate psoriasis, achieves positive top-line results Development trend of critical ...

INR:0296. free rummy An imported anti-inflammatory drug Otezla submitted for application in the United States for the treatment of mild to moderate plaque psoriasis Th ...